SCHEMBL969376

SCHEMBL969376

Cc1ncc2c3c(oc2n1)CN(CC(=O)N1CCN(C2CCC2)CC1)CC3

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.40
TMEM97 Q5BJF2 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
HRH3 Q9Y5N1 4/20 0.34
CBX7 O95931 3/20 0.34
CDYL2 Q8N8U2 3/20 0.34
CDYL Q9Y232 3/20 0.34
KDM4E B2RXH2 4/20 0.34
ALDH1A1 P00352 4/20 0.34
NPSR1 Q6W5P4 2/20 0.34
CDY1; CDY1B Q9Y6F8 1/20 0.34
HTT P42858 1/20 0.34
HSD17B10 Q99714 2/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
MAPT P10636 2/20 0.33
G6PD P11413 1/20 0.33
HPGD P15428 1/20 0.33
CACNA1B Q00975 1/20 0.33
APBA1 Q02410 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL967205 0.89 PARP1 (0.39) PARP1HRH3CBX7CDYL2CDYL
SCHEMBL971322 0.89 PARP1 (0.39) PARP1TMEM97HRH3CBX7CDYL2
SCHEMBL12920066 0.88 PARP1 (0.40) PARP1TMEM97SIGMAR1HRH3CBX7
SCHEMBL967866 0.88 PARP1 (0.40) PARP1TMEM97SIGMAR1HRH3CBX7
SCHEMBL969526 0.87 HRH3 (0.39) PARP1HRH3CBX7CDYL2CDYL
SCHEMBL967329 0.87 PARP1 (0.39) PARP1TMEM97HRH3CBX7CDYL2
SCHEMBL967576 0.86 PARP1 (0.42) PARP1HRH3KDM4EALDH1A1NPSR1
SCHEMBL967841 0.85 KDM4E (0.39) PARP1HRH3CBX7CDYL2CDYL
SCHEMBL969868 0.82 PARP1 (0.42) PARP1HRH3CBX7CDYL2CDYL
SCHEMBL969087 0.80 TSHR (0.36) PARP1HRH3CBX7CDYL2CDYL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
WO-2009003003-A2 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 PARP1 2898/4885TMEM97 67/4885SIGMAR1 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.